Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC Meeting Abstract
| Authors: | Kowanetz, M.; Zou, W.; Shames, D. S.; Cummings, C.; Rizvi, N.; Spira, A. I.; Frampton, G. M.; Leveque, V.; Flynn, S.; Mocci, S.; Shankar, G.; Funke, R.; Ballinger, M.; Waterkamp, D.; Sandler, A.; Hampton, G.; Amler, L.; Hegde, P. S.; Hellmann, M. |
| Abstract Title: | Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC |
| Meeting Title: | 41st European Society for Medical Oncology Congress (ESMO) |
| Journal Title: | Annals of Oncology |
| Volume: | 27 |
| Issue: | Suppl. 6 |
| Meeting Dates: | 2016 Oct 7-11 |
| Meeting Location: | Copenhagen, Denmark |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2016-10-01 |
| Start Page: | vi23 |
| Language: | English |
| ACCESSION: | WOS:000393912500077 |
| DOI: | 10.1093/annonc/mdw363.25 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 77P -- Source: Wos |
